Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Exanthema Market Outlook

The exanthema market size was valued at USD 1390.27 million in 2023, driven by the increasing incidence of viral and bacterial infections and innovations in diagnostic methods across the 8 major markets. The market size is anticipated to grow at a CAGR of 6.10% during the forecast period of 2024-2032 to achieve a value of USD 2231.8 million by 2032.

Exanthema Market Overview

Exanthema is commonly triggered by infections, often viral, and can manifest as a response to toxins from the organism, skin damage, or an immune reaction. These rashes, nonspecific in nature, show as spots or blotches that may or may not cause itching. They typically spread widely across the body, often more prominently on the trunk than the limbs. Before the rash appears, patients might experience a range of general symptoms including fever, malaise, headaches, reduced appetite, abdominal pain, irritability, muscle aches, and pains.

The exanthema market growth is driven by the rising incidence of viral and bacterial infections, causing skin rashes and related diseases. The escalating prevalence of infectious diseases like measles, rubella, and chickenpox, is significantly contributing to increased exanthema cases, which is expected to require enhanced attention to provide preventive measures and vaccinations, further propelling the market growth. The market is further driven by improvements in healthcare facilities and infrastructure to provide better diagnosis, treatment, and management of exanthemas, encouraging more people to seek medical care.

Consequently, the market is also witnessing innovations in diagnostic methods such as molecular testing and serological assays, acting as major drivers to further bolster the exanthema market demand. Governments and healthcare organizations are launching interesting initiatives to promote vaccination campaigns, especially for diseases linked to exanthemas are contributing to increased market demand.

Initiatives Aiding the Market Growth

The market demand is anticipated to experience significant growth due to a combination of factors such as national and international organizations acting and launching initiatives toward the prevention of exanthema in regions. For instance, the IA2030 Measles & Rubella Partnership, a collaborative initiative led by multiple prominent entities in the field of healthcare and immunization including the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccine Alliance, the Bill and Melinda Gates Foundation, UNICEF, and the World Health Organization (WHO). Such initiatives are aligned towards a common goal of spreading awareness regarding exanthema, likely to contribute significantly to the rising exanthema market share.

Surge in Supplies Due to Unforeseen Outbreak

The market is witnessing a surge in demand for increased treatment supplies and drugs due to the emergence of the condition in some regions. For instance, a recent surge in measles cases in Romania including 460 confirmed cases by August 2023 and significant outbreaks in several counties, has escalated the urgency for effective interventions and preventive measures, elevating the demand for relevant treatments and vaccinations. The market growth is expected to witness escalation owing to the sudden surge in the demand for treatment and vaccination in affecting regions.

FDA Approvals to Aid the Market Growth

The exanthema market growth is also driven by new FDA approvals creating a wave of hope for healthcare professionals and patients. For instance, Merck's groundbreaking announcement of the FDA's approval for intramuscular administration of the MMRV family vaccines—M-M-R®II, VARIVAX®, and ProQuad® marks have also collectively marked a pivotal advancement. This alteration from the conventional subcutaneous injection to intramuscular administration broadens the vaccination landscape enhancing convenience and accessibility as well. Such developments signify promising increased demand for the exanthem market in the forecast period.

Exanthema Market Segmentations

Market Breakup by Disease Type

  • Bacterial
  • Viral
  • Others

Market Breakup by Therapy Type

  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy

Market Breakup by Treatment

  • Anti-Pyretic
  • Emollients
  • Liquids
  • Others

Market Breakup by Drugs

  • Corticosteroids
  • Antiseizure Agents
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • China

Exanthema Market Regional Analysis

Considering the geographical landscape, the United States is leading the regional market. The market is expected to dominate in the forecast period due to factors such as the presence of the largest patient pool for exanthema and also representing the largest market for its treatment.

The latest data by the CDC Centers for Disease Control and Prevention has revealed that more than 3,700 babies were born with syphilis in 2022, which was more than 10 times the number in 2012. The increase in newborn syphilis follows rising syphilis cases among women of reproductive age combined with social and economic factors that create barriers to high-quality prenatal care and ongoing declines in the prevention infrastructure and resources.

The United States has seen a rise in cases of syphilis and congenital syphilis, leading senior leadership at the U.S. Department of Health and Human Services (HHS) to establish the National Syphilis and Congenital Syphilis Syndemic Federal Taskforce. This task force is dedicated to leading a national public health response to address the issue.

Exanthema Market: Competitor Landscape

In February 2023, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicella-zoster virus (VZV). Shingles affects millions of people around the world each year.

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Mylan N.V.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceutical Industries
  • Bristol Myers Squibb Company
  • Bayer AG
  • Sun Pharmaceutical Industries
  • Manus Aktteva Biopharma LLP
  • Perrigo Company plc
  • Novartis AG
  • GSK Plc.
  • CIRON Drugs & Pharmaceuticals Pvt. Ltd.
  • Concord Laboratories

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Therapy Type
  • Treatment
  • Drugs
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Disease Type
  • Bacterial
  • Viral
  • Others
Breakup by Therapy Type
  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
Breakup by Treatment
  • Anti-Pyretic
  • Emollients
  • Liquids
  • Others
Breakup by Drugs
  • Corticosteroids
  • Antiseizure Agents
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • China
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc 
  • F. Hoffmann-La Roche Ltd
  • Mylan N.V.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceutical Industries
  • Bristol Myers Squibb Company
  • Bayer AG
  • Sun Pharmaceutical Industries
  • Manus Aktteva Biopharma LLP
  • Perrigo Company plc
  • Novartis AG
  • GSK Plc.
  • CIRON Drugs & Pharmaceuticals Pvt. Ltd.
  • Concord Laboratories

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The market attained a value of about USD 1390.27 million in 2023 driven by increasing bacterial infections.

The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2024-2032 and is likely to reach a market value of USD 2231.8 million by 2032.

The market demand is propelled by the launch of effective and collaborative initiatives led by multiple prominent entities in the field of healthcare and immunization, the increasing cases of syphilis, the surge in supplies due to the measles outbreak in Romania, the increasing number of clinical trials by the market players to bring the best and effective treatment for exanthema in the market.

The new FDA approvals such as the FDA's approval for intramuscular administration of the MMRV family vaccines M-M-R®II, VARIVAX®, and ProQuad® marks, marking pivotal advancements are a major trend influencing the market growth.

The 8 major regions of the market include the United States, EU-4, the United Kingdom, Japan, and China.

Bacterial and viral diseases among others may trigger exanthema in people.

Exanthema can be treated by chemotherapy, radiation therapy, and targeted therapy.

This medical condition can be cured by anti-pyretic, emollients, and liquids, among others. 

Corticosteroids and antiseizure agents among others can be used to treat exanthema in the market.

Routes of administration include oral, and parenteral, among others.

Distribution channels include hospital pharmacies and retail pharmacies.

Key players involved in the market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries, Bristol Myers Squibb Company, Bayer AG, Sun Pharmaceutical Industries, Manus Aktteva Biopharma LLP, Perrigo Company plc, Novartis AG, GSK Plc., CIRON Drugs & Pharmaceuticals Pvt. Ltd., and Concord Laboratories.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124